Cidara Therapeutics (CDTX) investor relations material

Deal rationale and strategic fit

• Acquisition advances a science-led strategy, diversifying and expanding the pipeline with a first-in-class, long-acting, strain-agnostic antiviral for influenza, targeting significant unmet needs in high-risk and immunocompromised populations.

• CD388 complements the existing respiratory and infectious disease portfolio and is expected to address a large addressable population, with over 110 million high-risk individuals in the U.S. alone.

• The deal aligns with a strategy of adding innovative external science to strengthen the pipeline and drive growth into the next decade.

Financial terms and conditions

• Acquisition price is $221.50 per share, totaling approximately $9.2 billion, with up to $600 million in milestone payments to Johnson & Johnson included in GAAP results.

• Transaction will be financed primarily through new debt and commercial paper, with no impact on credit rating.

• The deal will be accounted for as an asset acquisition, resulting in a $9 billion R&D expense charge next year and a negative EPS impact of $0.30 in the first 12 months post-close.

Synergies and expected cost savings

• CD388 fits well with the current infrastructure, requiring minimal additional resources for launch and leveraging global development, regulatory, and commercial capabilities.

• Commercial model leverages existing relationships with high-risk patient populations and healthcare systems, creating durable commercial opportunities.